New ADCC technology based on synthetic biology

摘要

New synthetic biology based ADCC techniques are provided that enhance or enable ADCC responses. The novel ADCC technology can be used to prevent or treat cancer, infectious, inflammatory or autoimmune diseases and other diseases where removal of diseased cells is desirable. A genetic construct encoding a transmembrane chimeric receptor comprising an ectodomain having an antibody Fc binding affinity higher than the antibody Fc binding affinity of human CD16, a transmembrane domain, and an endodomain for mediating ADCC activation and amplification.